AgeX Therapeutics Inc.

0.5738-0.0355-5.83%Vol 51.87K1Y Perf -58.83%
Jun 24th, 2022 16:00 DELAYED
BID0.6000 ASK0.6800
Open0.6000 Previous Close0.6093
Pre-Market- After-Market0.60
 - -  0.03 4.57%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     30.44
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.82 
Earnings Rating
Neutral
Market Cap21.77M 
Earnings Date
12th Aug 2022
Alpha-0.03 Standard Deviation0.26
Beta1.40 

Today's Price Range

0.57380.6400

52W Range

0.51621.71

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.48%
1 Month
-25.84%
3 Months
-35.18%
6 Months
-4.37%
1 Year
-58.83%
3 Years
-85.29%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AGE0.5738-0.0355-5.83
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
0.00
0.20
0.41
0.88
-5.50
Leverage Ratio -0.30
ProfitabilityValueIndustryS&P 500US Markets
440.00
-22 488.60
-22 114.30
-22 097.60
-
RevenueValueIndustryS&P 500US Markets
35.00K
0.00
-68.42
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.07-
Q03 2021--0.05-
Q02 2021--0.07-
Q01 2021--0.05-
Q03 2020--0.07-
Q02 2020--0.07-
Q01 2020--0.08-
Q04 2019--0.08-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume51.87K
Shares Outstanding37.94K
Shares Float21.45M
Trades Count129
Dollar Volume30.89K
Avg. Volume34.30K
Avg. Weekly Volume26.06K
Avg. Monthly Volume30.68K
Avg. Quarterly Volume46.17K

AgeX Therapeutics Inc. (AMEX: AGE) stock closed at 0.5738 per share at the end of the most recent trading day (a -5.83% change compared to the prior day closing price) with a volume of 51.87K shares and market capitalization of 21.77M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. AgeX Therapeutics Inc. CEO is Michael D. West.

The one-year performance of AgeX Therapeutics Inc. stock is -58.83%, while year-to-date (YTD) performance is -47.36%. AGE stock has a five-year performance of %. Its 52-week range is between 0.5162 and 1.71, which gives AGE stock a 52-week price range ratio of 4.82%

AgeX Therapeutics Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 14.33, a price-to-sale (PS) ratio of 672.35, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -316.30%, a ROC of -319.78% and a ROE of 105.55%. The company’s profit margin is -%, its EBITDA margin is -22 114.30%, and its revenue ttm is $35.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from AgeX Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AgeX Therapeutics Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for AgeX Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AgeX Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AgeX Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AgeX Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.61, ATR14 : 0.08, CCI20 : -146.34, Chaikin Money Flow : -0.31, MACD : -0.04, Money Flow Index : 18.62, ROC : -21.48, RSI : 37.07, STOCH (14,3) : 0.00, STOCH RSI : 0.06, UO : 32.21, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AgeX Therapeutics Inc. in the last 12-months were: Michael D. West (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

AgeX Therapeutics Inc.

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop innovative medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1. And iTR drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon.

CEO: Michael D. West

Telephone: +1 510 871-4190

Address: 1010 Atlantic Avenue, Alameda 94501, CA, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

78%22%

Bearish Bullish

65%35%

Bearish Bullish

69%31%

News

Stocktwits